Patent EP0144243A1 successfully refreshed from Google Patents.
EP0144243A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Analgesic compositions
Assignee: COLMAN PRODUCTS Ltd
•
Filing: 1984-12-05
•
Granted: —
•
Expires: 2004-12-05
Abstract
Abstract An analgesic composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine. Preferably the parenteral dosage form contains naloxone and buprenorphine within the weight ratio of 1:3 to 1:1 and the sublingual form within the ratio 1:2 to 2:1.
Inventors
- 👤 John William Lewis
- 👤 John Gareth Lloyd-Jones
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 21:45
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0056; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K9/0019; A61P; A61P25/00; A61P25/04; A61P43/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
41 words
An analgesic composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine.
Claim 2
Dependent Claim
41 words
An analgesic composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine.
Claim 3
Dependent Claim
26 words
A pharmaceutical composition according to Claim 1 in parenteral dosage form wherein the weights of naloxone and buprenorphine are within the ratio of 1:3 to 1:1.
Claim 4
Dependent Claim
26 words
A pharmaceutical composition according to Claim 2 in unit dosage form for parenteral administration wherein the weight of buprenorphine is between about 0.3 to about 0.6mg.
Claim 5
Dependent Claim
26 words
A pharmaceutical composition according to Claim 1 in sublingual dosage form wherein the weights of naloxone and buprenorphine are within the ratio of 1:2 to 2:1.
Claim 6
Dependent Claim
26 words
A pharmaceutical composition according to Claim 4 in unit dosage form for sublingual administration wherein the weight of buprenorphine is between about 0.1 to about 0.6mg.
Claim 7
Dependent Claim
48 words
A pharmaceutical composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine for use in the treatment of pain.
Claim 8
Dependent Claim
48 words
A pharmaceutical composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine for use in the treatment of pain.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.